TURIN. No derogation. This is the summary of the note sent to the ASL in recent days – the sender is Dirmei, the operative arm of the Region in the fight against the Covid emergency – to avoid drift. The very delicate issue is access to health facilities, moreover in the recovery phase of the virus. Yesterday almost 500 new infections (483) – equal to 0.8% of 59,377 swabs performed, of which 52,664 antigenic -, unchanged hospitalizations in intensive care (24) but + 11 in ordinary wards (253), over 5 thousand ( 5,512 people in solitary confinement), fortunately no deaths reported.
Hence the prudence of the Dirmei and the invitation to health companies so that access to the facilities is granted only to patients and subjects exempt from the vaccination campaign, a status to be proven with medical certification, to those who have been in possession of the Green Pass for at least 14 days, to those who tested negative for the swab or to subjects recovered from Covid in the last 6 months, and I am able to prove it. This is not a coincidence, considering that, after the entry into force of the Green Pass, there have been several cases of people who asked to be allowed to enter hospitals by presenting a simple self-certification.
On the front of the fight against the virus, and those that could follow it, the councilor for applied research against Covid, Matteo Marnati, announces the doubling in 2022 of the Arpa Molecular Biology Center in La Loggia with 7 million euros foreseen in the Defr, the Document of Regional Economy and Finance: this is because, he explains, “the epidemic has shown beyond any doubt that qualified personnel are needed”.
On the vaccine front, on the other hand, the Amedeo di Savoia hospital participates in “SoberanaPlusTurin”, a clinical study carried out in Cuba and in Italy for people vaccinated with vaccines authorized in the European Union (Pfizer, Moderna, AstraZeneca, Johnson & Johnson) and who receive as a third dose the Cuban vaccine SoberanaPlus, made by the Finlay Institute of Vaccines of Havana. The vaccination will take place in Cuba, as part of the clinical study authorized by the Cuban regulatory authority Cecmed, and then return to Italy, where a sample will be taken with measurement of the specific antibody response by the Laboratory of Microbiology and Virology 28 days after vaccination. and the Amedeo University Clinic.
A total of 14,772 people were vaccinated yesterday in Piedmont: 3,868 were given the second dose, 9,251 the third. –
.